Clinical Neuromuscular

Inflammatory Myopathies

Inflammatory Myopathies

What You'll Learn

  • Four major types: Dermatomyositis (DM), Polymyositis (PM), Immune-Mediated Necrotizing Myopathy (IMNM), and Inclusion Body Myositis (IBM) — PM is now rare/diagnosis of exclusion; many previously labeled PM are actually IMNM
  • IBM is the most common inflammatory myopathy in patients >50: Insidious, asymmetric, targets finger flexors (FDP) + quadriceps; DOES NOT respond to immunosuppression
  • DM = skin + proximal weakness + cancer risk: Heliotrope rash, Gottron papules; 10–15% malignancy in adults >40; TIF1-γ antibody has strongest cancer association
  • IMNM = very high CK + necrosis without inflammation: Anti-SRP (severe, cardiac) and anti-HMGCR (statin-associated); requires aggressive immunosuppression
  • Biopsy is diagnostic: Perifascicular atrophy = highly characteristic of DM (also seen rarely in antisynthetase syndrome with perifascicular pattern); rimmed vacuoles = IBM; necrosis/regeneration with MAC = IMNM; endomysial CD8+ T cells = PM
  • Antisynthetase syndrome: Myositis + ILD + arthritis + Raynaud + mechanic's hands + fever; Jo-1 most common antibody; ILD may dominate
  • Treatment: DM/PM/IMNM → steroids + steroid-sparing agent ± IVIg/rituximab; IBM → no proven effective therapy (exercise + supportive care)
HighYield Pearls
  • DM hallmark: proximal symmetric weakness + skin (heliotrope, Gottron papules, shawl/V sign, mechanic’s hands) + perifascicular atrophy on biopsy + MAC on capillaries (humoral/complement-mediated microangiopathy)
  • IBM = older adult (>50, M>F), insidious, ASYMMETRIC distal + proximal weakness with preferential finger flexor + quadriceps involvement, dysphagia, mild CK; steroid-unresponsive — never call it PM
  • IBM biopsy: endomysial inflammation + rimmed vacuoles + 15–18 nm filamentous inclusions on EM + TDP-43/p62 aggregates; anti-cN1A supportive but not sensitive
  • IMNM: severe proximal weakness + CK often >10,000 + necrotic/regenerating fibers with minimal inflammation; anti-HMGCR (statin-associated, persists after withdrawal — distinct from self-limited toxic statin myopathy) or anti-SRP; treat steroids + IVIG + immunosuppression
  • Antisynthetase syndrome: myositis + ILD + arthritis + Raynaud + mechanic’s hands + fever; anti-Jo-1 most common (also PL-7, PL-12, OJ, EJ, KS); ILD often dominates
  • Anti-MDA5: amyopathic DM + rapidly progressive ILD + skin ulcers/digital ischemia — high mortality, needs aggressive immunosuppression
  • Cancer-associated DM: anti-TIF1γ and anti-NXP2 — screen with age-appropriate malignancy workup (CT chest/abd/pelvis, ovarian/lung, PET-CT)
  • PM is a diagnosis of exclusion — most historical “PM” cases are IBM, IMNM, antisynthetase, or muscular dystrophy mimics; biopsy required (endomysial CD8+ T cells invading non-necrotic fibers + MHC-I upregulation)
  • Juvenile DM → calcinosis cutis (especially NXP-2); anti-Mi-2 → classic DM with good prognosis
  • MRI muscle STIR/T2 shows edema in active myositis — useful for biopsy targeting; ICI-associated myositis often overlaps with myasthenia/myocarditis with high mortality
🔍 Quick ReferenceClinical · EMG / labs / imaging · Biopsy / antibody / pathology
Clinical phenotype
  • Heliotrope rash + Gottron papules + shawl/V signDermatomyositis
  • Mechanic’s hands + arthritis + ILD + Raynaud + feverAntisynthetase syndrome
  • Finger flexor + quadriceps weakness + dysphagia + falls in older adultInclusion body myositis (IBM)
  • Markedly elevated CK + recent statin use + ongoing weakness despite withdrawalAnti-HMGCR IMNM
  • Rapidly progressive ILD + skin ulcers + amyopathic DMAnti-MDA5 DM
  • Juvenile DM + calcinosis cutisAnti-NXP2 (juvenile DM)
  • Cancer-associated DM in middle-aged adultAnti-TIF1γ / anti-NXP2
EMG / labs / imaging
  • Myopathic motor units (small polyphasic) + fibrillations/PSWsActive inflammatory myopathy
  • CK >10,000IMNM (typical); 1,000–10,000 → DM/PM; <2,000 with mild elevationIBM
  • MRI muscle STIR/T2 edemaActive myositis (useful for biopsy targeting)
  • MRI muscle fatty replacement of anterior thigh sparing rectus + medial gastroc/forearm flexorsIBM pattern
  • Elevated aldolase + LDHMyositis (supportive); ESR/CRP variable
Biopsy / antibody / pathology
  • Perifascicular atrophy + MAC on capillaries + perivascular B-cell/CD4 inflammationDermatomyositis
  • Rimmed vacuoles + 15–18 nm filaments + TDP-43/p62 inclusionsIBM
  • Necrotic + regenerating fibers with minimal inflammationIMNM
  • Endomysial CD8 invading non-necrotic fibers + MHC-I overexpressionPolymyositis
  • Anti-Jo-1 / PL-7 / PL-12 / OJ / EJ / KSAntisynthetase syndrome
  • Anti-Mi-2Classic DM, good prognosis
  • Anti-TIF1γ / anti-NXP2Cancer-associated DM
  • Anti-MDA5Amyopathic DM + rapidly progressive ILD
  • Anti-HMGCR / anti-SRPIMNM
  • Anti-cN1AIBM (supportive)
Classification

Four Major Types of Inflammatory Myopathy

Type Key Distinction
Dermatomyositis (DM) Skin rash + proximal weakness; complement-mediated microangiopathy; perifascicular atrophy on biopsy
Polymyositis (PM) Proximal weakness without skin rash; CD8+ T cell-mediated; now rare — diagnosis of exclusion after ruling out IBM, IMNM, and dystrophy
Immune-Mediated Necrotizing Myopathy (IMNM) Severe proximal weakness + very high CK; necrosis/regeneration with minimal inflammation; anti-SRP or anti-HMGCR antibodies
Inclusion Body Myositis (IBM) Insidious asymmetric weakness (finger flexors + quadriceps); rimmed vacuoles on biopsy; refractory to immunosuppression
💎 Board Pearl
  • PM is now considered a diagnosis of exclusion — many historical PM cases were actually IMNM or IBM; always check for IMNM antibodies and consider biopsy before labeling PM
  • If a “PM” patient does not respond to steroids, reconsider the diagnosis — think IBM (if older + distal weakness) or IMNM (if very high CK)
DM vs PM vs IBM vs IMNM — Master Comparison
Feature DM PM IMNM IBM
Age of onset Any age (adults + children) >18 years Any age >50 years
Sex F > M (2:1) F > M F > M M > F (3:1)
Onset Subacute (weeks–months) Subacute Acute/subacute Insidious (years)
Weakness pattern Proximal, symmetric Proximal, symmetric Proximal, symmetric, severe Proximal + distal, asymmetric (finger flexors + quadriceps)
Skin involvement Yes (hallmark) No No No
CK level Elevated (5–50×) Elevated (10–50×) Very high (often >10,000) Mild (1–10×)
Pathology Perifascicular atrophy; perimysial inflammation; complement (MAC) on capillaries Endomysial CD8+ T cells invading non-necrotic fibers Necrosis/regeneration; minimal/absent inflammation; MAC on capillaries Rimmed vacuoles; intracellular inclusions (amyloid, TDP-43, p62); endomysial CD8+ T cells
Key antibodies Mi-2, MDA5, TIF1-γ, NXP-2, SAE No specific MSA; antisynthetases (Jo-1, etc.) may occur but define antisynthetase syndrome rather than pure PM Anti-SRP, anti-HMGCR Anti-cN1A (~33–50%, up to 60% in some series)
Cancer risk 10–15% (highest with TIF1-γ) Low Moderate (especially anti-HMGCR) None
Treatment response Good Good Variable (often aggressive Rx needed) Poor/none
Dysphagia 20–30% Uncommon Uncommon ~60%
💎 Board Pearl
  • Older man + slow progressive weakness + finger flexors + quadriceps + rimmed vacuoles = IBM — the most tested inflammatory myopathy on boards
  • Very high CK (>10,000) + minimal biopsy inflammation = IMNM, not PM
  • Skin rash precedes or accompanies weakness = DM — if only skin and no weakness, it is amyopathic DM (check MDA5)
🔒

Continue reading — sign in

The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.